With Abcodia’s launch of the ROCA® test in the US, we wanted to deliver a candidate with the energy and enthusiasm to commercialize their offering and take their business to the next level
(PRWEB) June 09, 2015
National recruitment firm Slone Partners is pleased to announce the placement of Mrs. Nadia Altomare as President of North America at Abcodia, a specialist company engaged in the development of tests for early detection of cancer.
In this position, Mrs. Altomare will develop and implement the strategic business plan for the US operations, launch the company’s first early cancer detection product, the ROCA® test in the US, and build a high performing, successful, growing business.
The ROCA® test is a first-of-its-kind high performance test, which has been shown to detect over 86% of ovarian cancers in women with no symptoms 1,2 . Mrs. Altomare will also join the Board of Directors of the parent company Abcodia Ltd.
“I am delighted to join Abcodia at such an exciting time in its development,” said Mrs. Altomare. “ROCA® is a product with unprecedented performance for the earlier detection of ovarian cancer. The test represents a unique opportunity to address a significant clinical unmet need for any post-menopausal woman or pre-menopausal women with a clear family history of ovarian cancer. I look forward to launching the ROCA® test in the US market and to working closely with clinicians, patients, societies, regulatory bodies, and advocacy groups to advance the science of early cancer detection screening for ovarian cancer.”
This appointment follows Abcodia’s success in securing £5.25 million ($8m) of venture capital finance from Albion Ventures, Cambridge Innovation Capital, Scottish Equity Partners and UCL Business3, who have committed to invest in building a highly skilled team to support the launch of the ROCA® test in both US and UK markets later in 2015.
“With Abcodia’s launch of the ROCA® test in the US, we wanted to deliver a candidate with the energy and enthusiasm to commercialize their offering and take their business to the next level,” said Adam Slone, CEO of Slone Partners. “Abcodia is a passionate group, and with Nadia, we really found someone who was the right fit.”
On working with Slone Partners, Dr. Julie Barnes, Chief Executive Officer of Abcodia, said: “This was our first experience working with Slone Partners and I would not hesitate to work with them again. The quality of the candidates that they selected for this role was extremely high, which is a testament to their knowledge of where to find excellent candidates in this space. The attention to detail, communication, and decision making throughout the entire process was outstanding.”
On Mrs. Altomare’s joining Abcodia, Dr. Julie Barnes said: "Nadia shares our team's vision, mission, and passion. She is a seasoned healthcare executive with a proven track record in building successful global businesses.” Dr. Barnes continued, "With her significant experience in positioning technology start-ups for profitable growth, Nadia will be a tremendous asset to Abcodia. At this exciting time for our company, she will provide insight and perspective to guide the successful expansion of our business in the US market.”
About Mrs. Nadia Altomare
Mrs. Altomare has more than 20 years healthcare experience and an extensive knowledge in developing and implementing strategic plans to drive commercial growth in the life sciences, biotechnology, and diagnostic industries. She is a highly accomplished senior executive with an exceptional background in positioning commercial companies for growth, profitability and sustainable competitive advantage. Mrs. Altomare has held senior management positions in single & multi-product/service environments spanning from entrepreneurial to Fortune 500 companies.
Mrs. Altomare received an M.B.A from Northeastern University in Boston, Massachusetts, and a B.S. from The University of New York at Stony Brook in Stony Brook, New York.
Abcodia is a pioneering UK company engaged in the clinical and commercial development of promising tests for the early detection of cancer. The company’s first product to reach the market in 2015 will be the ROCA® test, to which Abcodia has an exclusive license for the early detection of ovarian cancer. In addition and in co-operation with University College London, Abcodia is leading technology developments in disease lifecycle utilizing the world’s largest serum biobank and clinical database ever developed, to evaluate potential tests for the early detection of disease, including all major cancers. In 2013 Abcodia formed an alliance with Cancer Research UK and Cancer Research Technology to discover and validate blood-based biomarkers that may be used in cancer screening.
About Slone Partners
Founded in 2000, Slone Partners is a premier executive search firm that specializes in recruitment for the diagnostics, life science tools, healthcare information technology and laboratory testing industries. Slone Partners has offices in Boston, New York, Washington, D.C. and San Francisco.
For more information on Slone Partners placements, please visit http://www.slonepartners.com